alexa Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Bioinformatics & Systems Biology

Bioinformatics & Systems Biology

Journal of Proteomics & Bioinformatics

Author(s): Ford D, Easton DF, Stratton M, Narod S, Goldgar D,

Abstract Share this page

Abstract The contribution of BRCA1 and BRCA2 to inherited breast cancer was assessed by linkage and mutation analysis in 237 families, each with at least four cases of breast cancer, collected by the Breast Cancer Linkage Consortium. Families were included without regard to the occurrence of ovarian or other cancers. Overall, disease was linked to BRCA1 in an estimated 52\% of families, to BRCA2 in 32\% of families, and to neither gene in 16\% (95\% confidence interval [CI] 6\%-28\%), suggesting other predisposition genes. The majority (81\%) of the breast-ovarian cancer families were due to BRCA1, with most others (14\%) due to BRCA2. Conversely, the majority of families with male and female breast cancer were due to BRCA2 (76\%). The largest proportion (67\%) of families due to other genes was found in families with four or five cases of female breast cancer only. These estimates were not substantially affected either by changing the assumed penetrance model for BRCA1 or by including or excluding BRCA1 mutation data. Among those families with disease due to BRCA1 that were tested by one of the standard screening methods, mutations were detected in the coding sequence or splice sites in an estimated 63\% (95\% CI 51\%-77\%). The estimated sensitivity was identical for direct sequencing and other techniques. The penetrance of BRCA2 was estimated by maximizing the LOD score in BRCA2-mutation families, over all possible penetrance functions. The estimated cumulative risk of breast cancer reached 28\% (95\% CI 9\%-44\%) by age 50 years and 84\% (95\% CI 43\%-95\%) by age 70 years. The corresponding ovarian cancer risks were 0.4\% (95\% CI 0\%-1\%) by age 50 years and 27\% (95\% CI 0\%-47\%) by age 70 years. The lifetime risk of breast cancer appears similar to the risk in BRCA1 carriers, but there was some suggestion of a lower risk in BRCA2 carriers <50 years of age.
This article was published in Am J Hum Genet and referenced in Journal of Proteomics & Bioinformatics

Relevant Expert PPTs

Relevant Speaker PPTs

  • David Köhne
    Principles and applications of optical switching assisted imaging and structuring schemes
    PPT Version | PDF Version
  • Dwi Astuti
    Phylogenetic position of Psittacula parakeet bird from Enggano Island, Indonesia based on analyses of cytochrome b gene sequences
    PPT Version | PDF Version
  • Inge Verbrugge
    Radio-immunotherapy of cancer: Therapeutic efficacy, underlying mechanisms and potential applications
    PPT Version | PDF Version
  • Mario Marques da Silva
    MIMO Systems and Applications
    PPT Version | PDF Version
  • Mehdi Shadaram
    Photonic Generation of Millimeter Wave Signals for Wireless Applications
    PPT Version | PDF Version
  • Akbar Vaseghi
    Gold nanoparticles for biomedical applications
    PPT Version | PDF Version
  • Osama O. Ibrahim
    Chemicals structure, properties, regulations and applications of non-nutritive-high intensity sweeteners
    PDF Version
  • Pauline Korukundo
    Pauline-Korukundo-Kiira-Motors-Project-Uganda-Development-of-the-KIIRA-EV-SMACK-Supervisory-Control-Firmware
    PPT Version | PDF Version
  • Francis Jeshira Reynoso
    The clinical phenotype of PIGN deficiency and consequences of defective GPI biogenesis
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Hamiyet Unal
    Constitutive activity in the angiotensin ii type 1 receptor: Discovery and applications
    PPT Version | PDF Version
  • Ana de Guzmán Báez
    Gypsum to Gypsum (GtoG): The European life project that aims to transform the gypsum waste market
    PPT Version | PDF Version
  • Constanca Figueiredo
    Generation of HLA Universal Platelets for Regenerative Applications
    PPT Version | PDF Version
  • Tianbiao Leo Liu
    Design and applications of redox active materials for advanced rechargeable batteries
    PPT Version | PDF Version
  • Vikas Kumar
    Potential Clinical Applications of Probiotics
    PPT Version | PDF Version

Recommended Conferences

  • 9th International Conference on Bioinformatics
    October 23-24, 2017 Paris, France
  • 9th International Conference and Expo on Proteomics
    October 23-25, 2017 Paris, France

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords